nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC22A5—Dactinomycin—testicular cancer	0.437	0.825	CbGbCtD
Ceftazidime—SLC22A6—Methotrexate—testicular cancer	0.0928	0.175	CbGbCtD
Ceftazidime—Immune system disorder—Cisplatin—testicular cancer	0.00107	0.00227	CcSEcCtD
Ceftazidime—Abdominal pain—Vinblastine—testicular cancer	0.00107	0.00227	CcSEcCtD
Ceftazidime—Hypotension—Bleomycin—testicular cancer	0.00107	0.00227	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—testicular cancer	0.00106	0.00225	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—testicular cancer	0.00105	0.00224	CcSEcCtD
Ceftazidime—Pruritus—Chlorambucil—testicular cancer	0.00104	0.00222	CcSEcCtD
Ceftazidime—Thrombocytopenia—Dactinomycin—testicular cancer	0.00104	0.00222	CcSEcCtD
Ceftazidime—Convulsion—Ifosfamide—testicular cancer	0.00104	0.0022	CcSEcCtD
Ceftazidime—Erythema multiforme—Etoposide—testicular cancer	0.00103	0.00218	CcSEcCtD
Ceftazidime—Paraesthesia—Bleomycin—testicular cancer	0.00103	0.00218	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—testicular cancer	0.00102	0.00218	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—testicular cancer	0.00102	0.00217	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—testicular cancer	0.00102	0.00216	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00101	0.00215	CcSEcCtD
Ceftazidime—Diarrhoea—Chlorambucil—testicular cancer	0.00101	0.00215	CcSEcCtD
Ceftazidime—Flushing—Etoposide—testicular cancer	0.00101	0.00214	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—testicular cancer	0.00101	0.00214	CcSEcCtD
Ceftazidime—Hypersensitivity—Vinblastine—testicular cancer	0.000996	0.00212	CcSEcCtD
Ceftazidime—Angiopathy—Etoposide—testicular cancer	0.000984	0.00209	CcSEcCtD
Ceftazidime—Immune system disorder—Etoposide—testicular cancer	0.00098	0.00208	CcSEcCtD
Ceftazidime—Pain—Bleomycin—testicular cancer	0.000977	0.00208	CcSEcCtD
Ceftazidime—Anaphylactic shock—Ifosfamide—testicular cancer	0.000976	0.00208	CcSEcCtD
Ceftazidime—Vision blurred—Cisplatin—testicular cancer	0.000972	0.00207	CcSEcCtD
Ceftazidime—Tremor—Cisplatin—testicular cancer	0.000966	0.00205	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—testicular cancer	0.000959	0.00204	CcSEcCtD
Ceftazidime—Nervous system disorder—Ifosfamide—testicular cancer	0.000957	0.00204	CcSEcCtD
Ceftazidime—Thrombocytopenia—Ifosfamide—testicular cancer	0.000956	0.00203	CcSEcCtD
Ceftazidime—Skin disorder—Ifosfamide—testicular cancer	0.000948	0.00202	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—testicular cancer	0.000944	0.00201	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—testicular cancer	0.00094	0.002	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—testicular cancer	0.00094	0.002	CcSEcCtD
Ceftazidime—Vomiting—Chlorambucil—testicular cancer	0.000938	0.00199	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—testicular cancer	0.000932	0.00198	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—testicular cancer	0.000931	0.00198	CcSEcCtD
Ceftazidime—Diarrhoea—Vinblastine—testicular cancer	0.000925	0.00197	CcSEcCtD
Ceftazidime—Dysgeusia—Etoposide—testicular cancer	0.000925	0.00197	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—testicular cancer	0.000924	0.00196	CcSEcCtD
Ceftazidime—Leukopenia—Cisplatin—testicular cancer	0.000923	0.00196	CcSEcCtD
Ceftazidime—Hypotension—Ifosfamide—testicular cancer	0.000912	0.00194	CcSEcCtD
Ceftazidime—Pain—Dactinomycin—testicular cancer	0.000911	0.00194	CcSEcCtD
Ceftazidime—Urticaria—Bleomycin—testicular cancer	0.000907	0.00193	CcSEcCtD
Ceftazidime—Body temperature increased—Bleomycin—testicular cancer	0.000903	0.00192	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—testicular cancer	0.000897	0.00191	CcSEcCtD
Ceftazidime—Dizziness—Vinblastine—testicular cancer	0.000894	0.0019	CcSEcCtD
Ceftazidime—Convulsion—Cisplatin—testicular cancer	0.000893	0.0019	CcSEcCtD
Ceftazidime—Nausea—Chlorambucil—testicular cancer	0.000876	0.00186	CcSEcCtD
Ceftazidime—Paraesthesia—Ifosfamide—testicular cancer	0.000876	0.00186	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000872	0.00185	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000871	0.00185	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—testicular cancer	0.00087	0.00185	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—testicular cancer	0.000862	0.00183	CcSEcCtD
Ceftazidime—Vomiting—Vinblastine—testicular cancer	0.00086	0.00183	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—testicular cancer	0.000855	0.00182	CcSEcCtD
Ceftazidime—Headache—Vinblastine—testicular cancer	0.000847	0.0018	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000846	0.0018	CcSEcCtD
Ceftazidime—Leukopenia—Etoposide—testicular cancer	0.000845	0.0018	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000843	0.00179	CcSEcCtD
Ceftazidime—Abdominal pain—Dactinomycin—testicular cancer	0.000842	0.00179	CcSEcCtD
Ceftazidime—Body temperature increased—Dactinomycin—testicular cancer	0.000842	0.00179	CcSEcCtD
Ceftazidime—Anaphylactic shock—Cisplatin—testicular cancer	0.000841	0.00179	CcSEcCtD
Ceftazidime—Hypersensitivity—Bleomycin—testicular cancer	0.000841	0.00179	CcSEcCtD
Ceftazidime—Pain—Ifosfamide—testicular cancer	0.000835	0.00177	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—testicular cancer	0.00083	0.00176	CcSEcCtD
Ceftazidime—Nervous system disorder—Cisplatin—testicular cancer	0.000825	0.00175	CcSEcCtD
Ceftazidime—Thrombocytopenia—Cisplatin—testicular cancer	0.000824	0.00175	CcSEcCtD
Ceftazidime—Convulsion—Etoposide—testicular cancer	0.000818	0.00174	CcSEcCtD
Ceftazidime—Skin disorder—Cisplatin—testicular cancer	0.000817	0.00174	CcSEcCtD
Ceftazidime—Pruritus—Bleomycin—testicular cancer	0.000808	0.00172	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—testicular cancer	0.000804	0.00171	CcSEcCtD
Ceftazidime—Nausea—Vinblastine—testicular cancer	0.000803	0.00171	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000799	0.0017	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000798	0.0017	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000792	0.00168	CcSEcCtD
Ceftazidime—Hypotension—Cisplatin—testicular cancer	0.000786	0.00167	CcSEcCtD
Ceftazidime—Hypersensitivity—Dactinomycin—testicular cancer	0.000785	0.00167	CcSEcCtD
Ceftazidime—Urticaria—Ifosfamide—testicular cancer	0.000775	0.00165	CcSEcCtD
Ceftazidime—Abdominal pain—Ifosfamide—testicular cancer	0.000772	0.00164	CcSEcCtD
Ceftazidime—Body temperature increased—Ifosfamide—testicular cancer	0.000772	0.00164	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—testicular cancer	0.000771	0.00164	CcSEcCtD
Ceftazidime—Anaphylactic shock—Etoposide—testicular cancer	0.000771	0.00164	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—testicular cancer	0.000759	0.00161	CcSEcCtD
Ceftazidime—Paraesthesia—Cisplatin—testicular cancer	0.000756	0.00161	CcSEcCtD
Ceftazidime—Thrombocytopenia—Etoposide—testicular cancer	0.000755	0.0016	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—testicular cancer	0.000752	0.0016	CcSEcCtD
Ceftazidime—Skin disorder—Etoposide—testicular cancer	0.000749	0.00159	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000732	0.00156	CcSEcCtD
Ceftazidime—Diarrhoea—Dactinomycin—testicular cancer	0.000729	0.00155	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000726	0.00154	CcSEcCtD
Ceftazidime—Vomiting—Bleomycin—testicular cancer	0.000726	0.00154	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—testicular cancer	0.000724	0.00154	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—testicular cancer	0.000724	0.00154	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—testicular cancer	0.000722	0.00153	CcSEcCtD
Ceftazidime—Hypotension—Etoposide—testicular cancer	0.00072	0.00153	CcSEcCtD
Ceftazidime—Rash—Bleomycin—testicular cancer	0.00072	0.00153	CcSEcCtD
Ceftazidime—Pain—Cisplatin—testicular cancer	0.000719	0.00153	CcSEcCtD
Ceftazidime—Dermatitis—Bleomycin—testicular cancer	0.000719	0.00153	CcSEcCtD
Ceftazidime—Hypersensitivity—Ifosfamide—testicular cancer	0.000719	0.00153	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000718	0.00153	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—testicular cancer	0.000712	0.00151	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—testicular cancer	0.00071	0.00151	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—testicular cancer	0.000696	0.00148	CcSEcCtD
Ceftazidime—Paraesthesia—Etoposide—testicular cancer	0.000692	0.00147	CcSEcCtD
Ceftazidime—Pruritus—Ifosfamide—testicular cancer	0.00069	0.00147	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—testicular cancer	0.000685	0.00146	CcSEcCtD
Ceftazidime—Nausea—Bleomycin—testicular cancer	0.000678	0.00144	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—testicular cancer	0.000677	0.00144	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—testicular cancer	0.000677	0.00144	CcSEcCtD
Ceftazidime—Vomiting—Dactinomycin—testicular cancer	0.000677	0.00144	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—testicular cancer	0.000676	0.00144	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000672	0.00143	CcSEcCtD
Ceftazidime—Rash—Dactinomycin—testicular cancer	0.000672	0.00143	CcSEcCtD
Ceftazidime—Diarrhoea—Ifosfamide—testicular cancer	0.000668	0.00142	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—testicular cancer	0.000668	0.00142	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—testicular cancer	0.000666	0.00142	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Etoposide—testicular cancer	0.000665	0.00141	CcSEcCtD
Ceftazidime—Body temperature increased—Cisplatin—testicular cancer	0.000665	0.00141	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—testicular cancer	0.00066	0.0014	CcSEcCtD
Ceftazidime—Pain—Etoposide—testicular cancer	0.000659	0.0014	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—testicular cancer	0.000657	0.0014	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—testicular cancer	0.000653	0.00139	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—testicular cancer	0.00065	0.00138	CcSEcCtD
Ceftazidime—Dizziness—Ifosfamide—testicular cancer	0.000645	0.00137	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—testicular cancer	0.000641	0.00136	CcSEcCtD
Ceftazidime—Nausea—Dactinomycin—testicular cancer	0.000633	0.00135	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—testicular cancer	0.000632	0.00134	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Etoposide—testicular cancer	0.00063	0.00134	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—testicular cancer	0.000627	0.00133	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—testicular cancer	0.000627	0.00133	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000621	0.00132	CcSEcCtD
Ceftazidime—Vomiting—Ifosfamide—testicular cancer	0.000621	0.00132	CcSEcCtD
Ceftazidime—Hypersensitivity—Cisplatin—testicular cancer	0.00062	0.00132	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—testicular cancer	0.000616	0.00131	CcSEcCtD
Ceftazidime—Rash—Ifosfamide—testicular cancer	0.000615	0.00131	CcSEcCtD
Ceftazidime—Dermatitis—Ifosfamide—testicular cancer	0.000615	0.00131	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—testicular cancer	0.000614	0.00131	CcSEcCtD
Ceftazidime—Urticaria—Etoposide—testicular cancer	0.000612	0.0013	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—testicular cancer	0.000611	0.0013	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—testicular cancer	0.000611	0.0013	CcSEcCtD
Ceftazidime—Body temperature increased—Etoposide—testicular cancer	0.000609	0.0013	CcSEcCtD
Ceftazidime—Abdominal pain—Etoposide—testicular cancer	0.000609	0.0013	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—testicular cancer	0.000608	0.00129	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000593	0.00126	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—testicular cancer	0.00059	0.00125	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—testicular cancer	0.000587	0.00125	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—testicular cancer	0.000585	0.00124	CcSEcCtD
Ceftazidime—Nausea—Ifosfamide—testicular cancer	0.00058	0.00123	CcSEcCtD
Ceftazidime—Diarrhoea—Cisplatin—testicular cancer	0.000576	0.00122	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—testicular cancer	0.000575	0.00122	CcSEcCtD
Ceftazidime—Hypersensitivity—Etoposide—testicular cancer	0.000568	0.00121	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—testicular cancer	0.000566	0.0012	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—testicular cancer	0.000564	0.0012	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—testicular cancer	0.000563	0.0012	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—testicular cancer	0.000554	0.00118	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—testicular cancer	0.000552	0.00117	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—testicular cancer	0.000549	0.00117	CcSEcCtD
Ceftazidime—Pruritus—Etoposide—testicular cancer	0.000545	0.00116	CcSEcCtD
Ceftazidime—Vomiting—Cisplatin—testicular cancer	0.000535	0.00114	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—testicular cancer	0.000533	0.00113	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—testicular cancer	0.000532	0.00113	CcSEcCtD
Ceftazidime—Rash—Cisplatin—testicular cancer	0.00053	0.00113	CcSEcCtD
Ceftazidime—Dermatitis—Cisplatin—testicular cancer	0.00053	0.00113	CcSEcCtD
Ceftazidime—Diarrhoea—Etoposide—testicular cancer	0.000527	0.00112	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—testicular cancer	0.000522	0.00111	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—testicular cancer	0.000518	0.0011	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—testicular cancer	0.000511	0.00109	CcSEcCtD
Ceftazidime—Dizziness—Etoposide—testicular cancer	0.00051	0.00108	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—testicular cancer	0.000508	0.00108	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—testicular cancer	0.000506	0.00108	CcSEcCtD
Ceftazidime—Nausea—Cisplatin—testicular cancer	0.0005	0.00106	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—testicular cancer	0.000499	0.00106	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—testicular cancer	0.00049	0.00104	CcSEcCtD
Ceftazidime—Vomiting—Etoposide—testicular cancer	0.00049	0.00104	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—testicular cancer	0.000487	0.00103	CcSEcCtD
Ceftazidime—Rash—Etoposide—testicular cancer	0.000486	0.00103	CcSEcCtD
Ceftazidime—Dermatitis—Etoposide—testicular cancer	0.000486	0.00103	CcSEcCtD
Ceftazidime—Headache—Etoposide—testicular cancer	0.000483	0.00103	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—testicular cancer	0.00048	0.00102	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000478	0.00102	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—testicular cancer	0.000474	0.00101	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—testicular cancer	0.000462	0.000982	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—testicular cancer	0.000462	0.000982	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—testicular cancer	0.000459	0.000975	CcSEcCtD
Ceftazidime—Nausea—Etoposide—testicular cancer	0.000458	0.000974	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—testicular cancer	0.000453	0.000963	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—testicular cancer	0.000452	0.000961	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—testicular cancer	0.00045	0.000957	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—testicular cancer	0.000448	0.000954	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000448	0.000952	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—testicular cancer	0.000438	0.000932	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—testicular cancer	0.000432	0.000919	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—testicular cancer	0.000431	0.000917	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—testicular cancer	0.000424	0.000902	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—testicular cancer	0.000424	0.000901	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—testicular cancer	0.000423	0.0009	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—testicular cancer	0.00042	0.000892	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—testicular cancer	0.000415	0.000882	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000414	0.000881	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—testicular cancer	0.000404	0.000858	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—testicular cancer	0.0004	0.00085	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000399	0.000848	CcSEcCtD
Ceftazidime—Pain—Methotrexate—testicular cancer	0.000395	0.00084	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—testicular cancer	0.000392	0.000834	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—testicular cancer	0.000391	0.000832	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—testicular cancer	0.000388	0.000826	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—testicular cancer	0.000388	0.000825	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—testicular cancer	0.000378	0.000803	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—testicular cancer	0.000374	0.000794	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000373	0.000793	CcSEcCtD
Ceftazidime—Pain—Epirubicin—testicular cancer	0.000369	0.000786	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—testicular cancer	0.000367	0.00078	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—testicular cancer	0.000365	0.000776	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—testicular cancer	0.000365	0.000776	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—testicular cancer	0.000359	0.000763	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—testicular cancer	0.000353	0.000751	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000345	0.000734	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—testicular cancer	0.000343	0.00073	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—testicular cancer	0.000342	0.000727	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—testicular cancer	0.000342	0.000726	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—testicular cancer	0.000342	0.000726	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—testicular cancer	0.00034	0.000723	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000327	0.000695	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—testicular cancer	0.000327	0.000695	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—testicular cancer	0.000318	0.000677	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—testicular cancer	0.000318	0.000675	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—testicular cancer	0.000316	0.000672	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—testicular cancer	0.000316	0.000672	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—testicular cancer	0.000316	0.000672	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—testicular cancer	0.000306	0.00065	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—testicular cancer	0.000305	0.000649	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—testicular cancer	0.000296	0.000629	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—testicular cancer	0.000295	0.000626	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—testicular cancer	0.000294	0.000624	CcSEcCtD
Ceftazidime—Rash—Methotrexate—testicular cancer	0.000291	0.000619	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—testicular cancer	0.000291	0.000618	CcSEcCtD
Ceftazidime—Headache—Methotrexate—testicular cancer	0.000289	0.000615	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—testicular cancer	0.000286	0.000608	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—testicular cancer	0.000283	0.000601	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—testicular cancer	0.000275	0.000584	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—testicular cancer	0.000274	0.000583	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—testicular cancer	0.000274	0.000582	CcSEcCtD
Ceftazidime—Rash—Epirubicin—testicular cancer	0.000272	0.000579	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—testicular cancer	0.000272	0.000579	CcSEcCtD
Ceftazidime—Headache—Epirubicin—testicular cancer	0.000271	0.000576	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—testicular cancer	0.000264	0.000562	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—testicular cancer	0.000257	0.000546	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—testicular cancer	0.000254	0.00054	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—testicular cancer	0.000252	0.000536	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—testicular cancer	0.000252	0.000535	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—testicular cancer	0.00025	0.000533	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—testicular cancer	0.000237	0.000505	CcSEcCtD
